GLP1减重宝典·2025-12-09 04:25Core Viewpoint - The article discusses the gender differences in the usage of GLP-1 medications for weight loss, highlighting that women are more likely to use these drugs compared to men, who prefer dietary and exercise changes [4][5][6]. Group 1: Gender Differences in Usage - Women are more proactive in considering GLP-1 medications like semaglutide for weight loss, while men tend to delay this consideration [5] - A significant majority of prescriptions for Wegovy (78%) and Zepbound (76%) are issued to female patients, despite similar obesity rates between genders (43% for men and 42% for women) [6] - Cultural expectations contribute to the lower usage of weight loss medications among men, as societal norms often allow them to be less concerned about obesity [7] Group 2: Interest in Broader Health Benefits - Men show increasing interest in semaglutide for its cardiovascular, kidney disease, and alcohol use disorder benefits, which may shift the gender balance in usage [8] - The approval of Wegovy for reducing heart disease risk and the anticipated approval of Zepbound for sleep apnea may enhance male interest in these medications [8] - The perception of these drugs as health therapies rather than merely cosmetic solutions is gaining traction among male patients [8] Group 3: Celebrity Influence - High-profile figures like Boris Johnson and Elon Musk have publicly shared their positive experiences with semaglutide, potentially influencing public perception and acceptance of the drug among men [9][13] - Johnson noted a significant decrease in appetite and food intake after starting semaglutide, while Musk reported a weight loss of 30 pounds (approximately 13.6 kg) with the help of the drug [11][13] - Other celebrities, such as Jon Gosselin, have also reported substantial weight loss results, further promoting the drug's effectiveness [15]